Triple negative breast carcinomas: Similarities and differences with basal like carcinomas

Applied Immunohistochemistry and Molecular Morphology

Volumn 17, Issue 6, 2009, Pages 483-494

  Lerma, Enrique ^a   Barnadas, Agusti ^b   Prat, Jaime ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Breast carcinoma; Estrogen receptor; HER2; Immunohistochemistry; Progesterone receptors

Indexed keywords

7 HYDROXYSTAUROSPORINE; AD 001; ANTHRACYCLINE; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; COMPLEMENTARY DNA; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ETOPOSIDE; GEFITINIB; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYOSIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; P CADHERIN; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN P63; PROTEIN S 100; RAD51 PROTEIN; SMOOTH MUSCLE ACTIN; TAXANE DERIVATIVE; TRABECTEDIN; UNCLASSIFIED DRUG; VIMENTIN;

APOPTOSIS; BASAL CELL; BREAST CARCINOMA; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE ARREST; CELL DIFFERENTIATION; CLINICAL TRIAL; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DRUG EFFICACY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRAIT; GENOTYPE; HISTOGENESIS; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LUNG NON SMALL CELL CANCER; MEDULLARY CARCINOMA; METASTASIS; MYOEPITHELIUM CELL; OVARY CARCINOMA; OVERALL SURVIVAL; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; SPINDLE CELL CARCINOMA; TRIPLE NEGATIVE BREAST CARCINOMA; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; CELL TRANSFORMATION, NEOPLASTIC; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; INCIDENCE; KERATINS; MAMMARY GLANDS, HUMAN; MYELOID PROGENITOR CELLS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL;

EID: 74249083841     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181a725eb     Document Type: Review

References (146)

1. Jemal A, Sieger R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Ries LAG, Melbert D, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD: http://seer.cancer. gov/csr/1975-2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008.
3. Carlson RW, et al. Breast cancer. NCCN practice guidelines in oncology (v2.2008). www. Nccn.org
4. Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol. 2005;23:2716-2725.
5. Early Breast Cancer Conservative Trialist. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1817.
6. Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective randomized clinical trials. Clin Cancer Res. 2005;11:6598-6607.
7. Wolff AC, Hammond ME, Schwartz JN, et al. American society of clinical oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-147.
8. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
9. White J, Morrow M, Moughan J, et al. Compliance with breastconservation standards for patients with early-stage breast carcinoma. Cancer. 2003;97:893-904.
10. Elledge RM, Fuqua SAW. Estrogen and progesterone receptors. In: Harris H, ed. Diseases of the Breast. Philadelphia: Lippincott Williams & Wilkins; 2000:47.
11. Fitzgibbons FK, Page DL, Weaver D, et al. Prognostic factors in breast cancer: College of American pathologists consensus statement 1999. Arch Pathol Lab Med, 2000;124:966-978.
12. Bardou V-J, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21:1973-1979.
13. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
14. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
15. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-10874.
16. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418-8423.
17. Van't Veer LJ, Dai H, Van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536.
18. Van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002;161:1991-1996.
19. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population based study. Proc Natl Acad Sci USA. 2003;100: 10393-10398.
20. Van de Vijver MJ, He YD, Van't Veer LJ, et al. A gene expression signature as a predictor of survival in breast cancer. N Eng J Med. 2002;347:1999-2009.
21. Ma XJ, Wang Z, Ryan PD, et al. A two gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004;5:607-616.
22. Huang E, Cheng SH, Dressman H, et al. Gene expression predictors of breast cancer outcomes. Lancet. 2003;361:1590-1596.
23. Jones C, Ford E, Gillett C, et al. Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res. 2004;10:5988-5997.
24. Callagy G, Cattaneo E, Diago Y, et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol. 2003;12:27-34.
25. Diaz LK, Cryns VL, Symmans WF, et al. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol. 2007;14:419-430.
26. Tang P, Wang J, Bourne P. Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same? Hum Pathol. 2008;39:506-513.
27. Fadare O, Tavassoli FA. Clinical and pathologic aspects of basallike breast cancers. Nat Clin Pract Oncol. 2008;5:149-159.
28. Fadare O, Wang SA, Hileeto D. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset? Hum Pathol. 2008;39:331-336.
29. Fadare O, Tavassoli FA. The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Adv Anat Pathol. 2007;14: 358-373. Review.
30. Gusterson B. Do "basal-like" breast cancers really exist? Nature Review. Cancer. 2009;9:128-134.
31. Gusterson BA, Ross DT, Heath VJ, et al. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res. 2005;7:143-148.
32. Moll R, Franke WW, Schiller DL, et al. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11-24.
33. Moll R, Krepler R, Franke WW. Complex cytokeratin polypeptide patterns observed in certain human carcinomas. Differentiation. 1983;23:256-269.
34. Malzahn K, Mitze M, Thoenes M, et al. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch. 1998;433:119-129.
35. Dairkee SH, Ljung BM, Smith H, et al. Immunolocalization of a human basal epithelium specific keratin in benign and malignant breast disease. Breast Cancer Res. 1987;10:11-20.
36. Dent R, Trudeau M, Pritchard KI, et al. Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-4434.
37. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative earlystage breast cancer. J Clin Oncol. 2006;24:5652-5657.
38. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-2502.
39. Collett K, Stefansson IM, Eide J, et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev. 2005;14:1108-1112.
40. Kang SP, Martel M, Harris LN. Triple negative breast cancer: current understanding of biology and treatment options. Curr Opin Obstet Gynecol. 2008;20:40-46.
41. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and her-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26:10.1200/ JCO.2007.14.4287.
42. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple negative breast cancer. Cancer. 2007;109:25-32.
43. Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol. 2006;208:495-506.
44. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 2007;110:876-884.
45. Bertucci F, Finetti P, Cervera N, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 2006;66:4636-4644.
46. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95:1482-1485.
47. Lester S. The breast. In: Kumar V, Abbas AK, Fausto N, eds. Robbins and Cotran Pathologic Basis of Disease. Boston: Elsevier; 2005:1137-1138.
48. Deugnier MA, Faraldo MM, Janji B, et al. EGF controls the in vivo developmental potential of a mammary epithelial cell line possessing progenitor properties. J Cell Biol. 2002;159:453-463.
49. Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003;17:1253-1270.
50. Jarasch ED, Nagle RB, Kaufmann M, et al. Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. Hum Pathol. 1988;19:276-289.
51. Shackleton M, Vaillant F, Simpson KJ, et al. Generation of a functional mammary gland from a single stem cell. Nature. 2006;439:84-88.
52. Stingl J, Eirew P, Ricketson I, et al. Purification and unique properties of mammary epithelial stem cells. Nature. 2006;439: 993-997.
53. Asselin-Labat ML, Shackleton M, Stingl J, et al. Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst. 2006;98:1011-1014.
54. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007;14:2126-2132.
55. Wennmalm K, Calza S, Ploner A, et al. Gene expression in 16q is associated with survival and differs between Sorlie breast cancer subtypes. Genes Chromosomes Cancer. 2007;46:87-97.
56. Korsching E, Packeisen J, Liedtke C, et al. The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol. 2005;206:451-457.
57. Kim MJ, Ro JY, Ahn SH, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 2006;37:1217-1226.
58. Lerma E, Peiro G, Ramon T, et al. Immunohistochemical heterogeneity of 59 breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). Mod Pathol. 2007;20:1200-1207.
59. Bland KI, Menck HR, Scott-Conner CE, et al. The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer. 1998;83:1262-1273.
60. McGinnis LS, Menck HR, Eyre HJ, et al. National Cancer Data Base survey of breast cancer management for patients from low income zip codes. Cancer. 2000;88:933-945.
61. Fulford LG, Reis-Filho JS, Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 2007;9:R4.
62. Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68:3108-3114.
63. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329-2334.
64. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264-271.
65. Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49:22-34.
66. Dabbs DJ, Chivukula M, Carter G, et al. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol. 2006;19:1506-1511.
67. Tsuda H, Takarabe T, Hasegawa T, et al. Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones. Hum Pathol. 1999;10:1134-1139.
68. Tsuda H, Takarabe T, Hasegawa F, et al. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol. 2000;24:197-202.
69. Livasy CA, Perou CM, Karaca G. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol. 2007;38:197-204.
70. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol. 2006;19:617-621.
71. Korsching E, Jeffrey SS, Meinerz W, et al. Basal carcinoma of the breast revisited: an old entity with new interpretations. J Clin Pathol. 2008;61:553-561.
72. Turner N, Tutt A, Ashworth A. Hallmarks of "BRCAness" in sporadic cancers. Nat Rev Cancer. 2004;4:814-819.
73. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25:5846-5853.
74. Beger C, Pierce LN, Kruger M, et al. Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc Natl Acad Sci USA. 2001;98:130-135. (Pubitemid 32095875)
75. Welcsh PL, Lee MK, Gonzalez-Hernandez RM, et al. BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci USA. 2002;99:7560-7565.
76. Foschini MP, Eusebi V. Carcinomas of the breast showing myoepithelial cell differentiation. A review of the literature. Virchows Arch. 1998;432:303-310.
77. Foschini MP, Reis-Filho JS, Eusebi V, et al. Salivary gland-like tumours of the breast: surgical and molecular pathology. J Clin Pathol. 2003;56:497-506.
78. Hayes M. Update in pathology 2008 3rd Intercontinental congress of pathology. 2008: 33-40.
79. Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology. 2006;49:10-21.
80. Adem C, Reynolds C, Adlakha H, et al. Wide spectrum screening keratin as a marker of metaplastic spindle cell carcinoma of the breast: an immunohistochemical study of 24 patients. Histopathology. 2002;40:556-562.
81. Breuer A, Kandel M, Fisseler-Eckhoff A, et al. BRCA1 germline mutation in a woman with metaplastic squamous cell breast cancer. Onkologie. 2007;30:316-318.
82. Ellis IO, Schnitt SJ, Sastre-Garau X, et al. Invasive breast carcinoma. In: Tavassoli FA, Devilee P, eds. Tumors of the Breast and Female Genital Organs. Lyon: IARC press; 2003:13-59.
83. Davis WG, Hennessy B, Babiera G, et al. Metaplastic sarcomatoid carcinoma of the breast with absent or minimal overt invasive carcinomatous component: a misnomer. Am J Surg Pathol. 2005;29:1456-1463.
84. Rosen PP, Ernsberger D. Low-grade adenosquamous carcinoma. A variant of metaplastic mammary carcinoma. Am J Surg Pathol. 1987;11:351-358.
85. Sneige N, Yaziji H, Mandavilli SR, et al. Low-grade (fibromatosislike) spindle cell carcinoma of the breast. Am J Surg Pathol. 2001;25:1009-1016.
86. Korsching E, Packeisen J, Agelopoulos K, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest. 2002;82:1525-1533.
87. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-5374.
88. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expressión of luminar and basal cytokeratins in human breast carcinoma. J Pathol. 2004;203:661-671.
89. Laakso M, Loman N, Borg A, et al. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA-1 tumors. Mod Pathol. 2005;18:1321-1328.
90. Matos I, Dufloth R, Alvarenga M, et al. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005;447:688-694.
91. Arnes JB, Brunet JS, Stefansson I, et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res. 2005;11:4003-4011.
92. Potemski P, Kusinska R, Watala C, et al. Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology. 2005;69:478-485.
93. Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al. Prognostic significance of basal-like phenotype and fascin expression in nodenegative invasive breast carcinomas. Clin Cancer Res. 2006;12: 1533-1539.
94. Rakha EA, El-Sayed M, Green AR, et al. Breast carcinoma with basal differentiation: a proposal for pathology definition based on cytokeratin expression. Histopathology. 2007;50:434-438.
95. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, et al. Basal-like phenotype is not associated with patient survival in estrogenreceptor- negative breast cancers. Breast Cancer Res. 2007;9:R16.
96. Rodriguez-Pinilla SM, Rodriguez-Gil Y, Moreno-Bueno G, et al. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype. Am J Surg Pathol. 31:501-508.
97. Kreike B, van KM, Horlings H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007;9:R65.
98. Nieto Y, Nawaz F, Jones RB, et al. Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. J Clin Oncol. 2007;25:4405-4413.
99. Vincent-Salomon A, Gruel N, Lucchesi C, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res. 2007;9:R24. doi 10.1186/bcr1666. (Pubitemid 350215163)
100. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149-2158.
101. Cappuzzo F, Gregorc V, Rossi E, et al. Gefitinib in pretreated nonsmall-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol. 2003;21:2658-2663.
102. Faratian D, Barlett J. Predictive markers in breast cancer-the future. Histopathology. 2008;52:91-98.
103. Lambros MB, Natrajan R, Reis-Filho JS. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Pathol. 2007;38:1105-1122.
104. Tsuda H, Morita D, Kimura M, et al. Correlation of KIT and EGFR overexpression with ductal breast carcinoma of the solidtubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. Cancer Sci. 2005;96:48-53.
105. Tovey SM, Witton CJ, Bartlett JMS, et al. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res. 2004;6:R246-R251.
106. Rampaul RS, Pinder SE, Wencyk PM, et al. Epidermal growth factor receptor status in operable invasive breast cancer: is it of any prognostic value? Clin Cancer Res. 2004;10:2578.
107. Reis-Filho JS, Pinheiro C, Lambros MB, et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol. 2006;209:445-453.
108. Martin AM, Kanetsky PA, Amirimani B, et al. Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1? J Med Genet. 2003;40:e34.
109. Patocs A, Zhang L, Xu Y, et al. Breast-Cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med. 2007;357: 2543-2551.
110. Gasco M, Yulug IG, Crook T. TP53 mutations in familial breast cancer: functional aspects. Hum Mutat. 2003;21:301-306.
111. Laakso M, Tanner M, Nilsson J, et al. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res. 2006;12:4185-4191.
112. Tsuda H, Tani Y, Weisenberger J, et al. Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated- type breast carcinomas with "stem-cell-like" features. Cancer Sci. 2005;96:333-339.
113. Hungermann D, Buerger H, Oehlschlegel C, et al. Adenomyoepithelial tumors and myoepithelial carcinomas of the breast-a spectrum of monophasic and biphasic tumours dominated by immature myoepithelial cells. BMC Cancer. 2005;5:92. doi:01.1186/ 1471-2407-5-92.
114. Azoulay S, Laé M, Fréneaux P, et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol. 2005;18: 1623-1631.
115. Kokkinos MI, Wafai R, Wong MK, et al. Vimentin and epithelialmesenchymal transition in human breast cancer-observations in vitro and in vivo. Cells Tissues Organs. 2007;185:191-203.
116. Reis-Filho JS. Re: Korsching E, Packeisen J, Liedtke C, et al. The origin of vimentin expression in invasive breast cancer: epithelialmesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol. 2005;206:451-457. 207:367-369; author reply 370-1361
117. Rodriguez-Pinilla SM, Sarrió D, Honrado E, et al. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinoma. J Clin Pathol. 2007;60:1006-1012.
118. Gilles C, Newgreen D, Sato H, et al. Matrix metalloproteases and epithelial-to mesenchymal transition: implications for carcinoma metastasis. In: Savagner P, ed. Rise and Fall of Epithelial Phenotype. Georgetown: Landes Bioscience Publishers; 2004: 297-315. www.eurekah.com.
119. Bourdon JC. p53 and its isoforms in cancer. Br J Cancer. 2007;97:277-282 [Epub 2007 Jul 17].
120. Reis-Filho JS, Schmitt FC. Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker. Adv Anat Pathol. 2002;9:280-289.
121. Stefanou D, Batistatou A, Nonni A, et al. p63 expression in benign and malignant breast lesions. Histol Histopathol. 2004;19:465-471.
122. Paredes J, Correia AL, Ribeiro AS, et al. P-cadherin expression in breast cancer: a review. Breast Cancer Res. 2007;9:214. doi:10.1186/bcr1744. (Pubitemid 350215180)
123. Gamallo C, Moreno-Bueno G, Sarrio D, et al. The prognostic significance of P-cadherin in infiltrating ductal breast carcinoma. Mod Pathol. 2001;14:650-654.
124. Paredes J, Milanezi F, Viegas L, et al. P-cadherin expression is associated with high-grade ductal carcinoma in situ of the breast. Virchows Arch. 2002;440:16-21. (Pubitemid 34143345)
125. Savage K, Maryou BK, Lambros D, et al. Caveolin-1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res. 2007;13:90-101.
126. Carpenter PM, Wang-Rodriguez J, Owen T, et al. Laminin-5 expression in metaplastic breast carcinomas. Am J Surg Pathol. 2008;32:345-353.
127. Diaz LK, Cristofanilli M, Zhou X, et al. Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer. Mod Pathol. 2005;18:1165-1175.
128. Li H, Cherukuri P, Li N, et al. Nestin is expressed in the basal/ myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res. 2007;67: 501-510.
129. Reis-Filho JS, Milanezi F, Silva P, et al. Maspin expression in myoepithelial tumors of the breast. Pathol Res Pract. 2001;197: 817-821.
130. Balic M, Lin H, Young L, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res. 2006;12:5615-5621.
131. Honeth G, Bendahl PO, Ringné r M, et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008;10:R53. [Epub 2008 Jun 17].
132. Charafe-Juaffret E, Ginestier C, Monville F, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene. 2006;25:2273-2284.
133. Reis-Filho JS, Steele D, Di Palma S, et al. Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod Pathol. 2006;19:307-319.
134. Ribeiro-Silva A, Ribeiro do Vale F, Zucoloto S. Vascular endothelial growth factor expression in the basal subtype of breast carcinoma. Am J Clin Pathol. 2006;125:512-518.
135. Umemura S, Yoshida S, Ohta Y, et al. Increased phosphorylation of Akt in triple-negative breast cancers. Cancer Sci. 2007;98: 1889-1892.
136. Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, et al. Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol. 2007;20:474-481.
137. Hasegawa M, Moritani S, Murakumo Y, et al. CD109 expression in basal-like breast carcinoma. Pathol Int. 2008;58:288-294.
138. Subhawong AP, Subhawong T, Nassar H, et al. Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol. 2009;33:163-175.
139. Hanley K, Wang J, Bourne P, et al. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. Hum Pathol. 2008;39:386-392.
140. Rouzier R, Perou CM, Symans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678-5685.
141. Liedtke C, Mazouni CH, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer patients. J Clin Oncol. 2008;26:1275-1281.
142. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair deffect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917-921.
143. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794-7803.
144. Levesque AA, Fanous AA, Poh A, et al. Defective p53 signalling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest. Mod Cancer Ther. 2008;7:252-262.
145. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-2676.
146. Hollestelle A, Elstrodt F, Nagel JHA, et al. Phosphatidylinositol-3- OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res. 2007;5:195-201.